全文获取类型
收费全文 | 78977篇 |
免费 | 4965篇 |
国内免费 | 2220篇 |
专业分类
耳鼻咽喉 | 666篇 |
儿科学 | 1455篇 |
妇产科学 | 945篇 |
基础医学 | 7722篇 |
口腔科学 | 1138篇 |
临床医学 | 8790篇 |
内科学 | 10724篇 |
皮肤病学 | 1480篇 |
神经病学 | 8343篇 |
特种医学 | 2073篇 |
外国民族医学 | 10篇 |
外科学 | 5430篇 |
综合类 | 10719篇 |
现状与发展 | 3篇 |
一般理论 | 3篇 |
预防医学 | 5010篇 |
眼科学 | 1562篇 |
药学 | 12333篇 |
38篇 | |
中国医学 | 2872篇 |
肿瘤学 | 4846篇 |
出版年
2024年 | 108篇 |
2023年 | 1045篇 |
2022年 | 1781篇 |
2021年 | 2815篇 |
2020年 | 2568篇 |
2019年 | 2211篇 |
2018年 | 2319篇 |
2017年 | 2423篇 |
2016年 | 2340篇 |
2015年 | 2400篇 |
2014年 | 4774篇 |
2013年 | 5248篇 |
2012年 | 4383篇 |
2011年 | 5090篇 |
2010年 | 3930篇 |
2009年 | 3871篇 |
2008年 | 3932篇 |
2007年 | 3909篇 |
2006年 | 3416篇 |
2005年 | 3197篇 |
2004年 | 2679篇 |
2003年 | 2486篇 |
2002年 | 2010篇 |
2001年 | 1913篇 |
2000年 | 1604篇 |
1999年 | 1520篇 |
1998年 | 1381篇 |
1997年 | 1334篇 |
1996年 | 1138篇 |
1995年 | 1106篇 |
1994年 | 991篇 |
1993年 | 748篇 |
1992年 | 751篇 |
1991年 | 539篇 |
1990年 | 457篇 |
1989年 | 368篇 |
1988年 | 333篇 |
1987年 | 320篇 |
1986年 | 316篇 |
1985年 | 377篇 |
1984年 | 370篇 |
1983年 | 206篇 |
1982年 | 275篇 |
1981年 | 222篇 |
1980年 | 177篇 |
1979年 | 158篇 |
1978年 | 114篇 |
1977年 | 127篇 |
1976年 | 112篇 |
1973年 | 64篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
A. Hochsprung S. Escudero-Uribe A.J. Ibáñez-Vera G. Izquierdo-Ayuso 《Neurología (Barcelona, Spain)》2021,36(6):433-439
IntroductionPain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methodsThis study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.ResultsStatistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.ConclusionsTreatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. 相似文献
62.
More than just crushing: a prospective pre‐post intervention study to reduce drug preparation errors in patients with feeding tubes 下载免费PDF全文
63.
64.
目的 探讨丙泊酚复合瑞芬太尼喉罩全身麻醉(全麻)的效果。方法 62例腹腔镜、泌尿科、骨科、肛肠科、妇科等手术治疗的患者,随机分为实验组和对照组,每组31例。对照组采用常规气管插管静脉复合全麻,实验组给予靶控输注丙泊酚复合瑞芬太尼喉罩全麻。比较两组患者插入喉罩(插管)、插管1 min、插管3 min、拔出喉罩(拔管)1 min、拔管3 min时心率(HR)和平均动脉压(MAP)水平;不良反应发生情况、麻醉效果;全麻起效时间、维持全麻时间、术后苏醒时间。结果 实验组插管时、插管1 min、插管3 min、拔管1 min、拔管3 min的HR水平分别为(77.52±6.36)、(73.26±5.56)、(72.01±4.69)、(75.35±7.63)、(72.34±6.79)次/min,均低于对照组的(92.34±7.85)、(87.97±5.25)、(78.85±5.20)、(95.69±9.21)、(85.63±7.43)次/min,差异均具有统计学意义(P<0.05)。实验组插管时、插管1 min、插管3 min、拔管1 min、拔管3 min的MAP水平分别为(90.25±6.73)、(87.65±7.98)、(88.79±7.65)、(88.09±5.61)、(88.52±5.16)mm Hg(1 mm Hg=0.133 kPa),均低于对照组的(109.51±7.85)、(103.27±12.43)、(102.52±8.21)、(106.74±7.68)、(104.62±7.71)mm Hg,差异均具有统计学意义(P<0.05)。实验组不良反应发生率3.23%低于对照组的19.35%,差异具有统计学意义(P<0.05)。实验组麻醉总有效率96.77%均高于对照组的80.65%,差异均具有统计学意义(P<0.05)。实验组全麻起效、维持全麻、术后苏醒时间分别为(1.61±0.23)、(100.59±6.72)、(17.99±3.52)min,均短于对照组的(2.93±0.41)、(123.61±7.85)、(36.87±4.16)min,差异均具有统计学意义(P<0.05)。结论 针对腹腔镜等手术患者应用丙泊酚复合瑞芬太尼喉罩全麻对血液动力学影响小,不良反应发生率低,麻醉效果良好,降低对机体损伤,值得推广应用。 相似文献
65.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(10):e629-e644
IntroductionLenalidomide plus dexamethasone is effective and well tolerated in relapsed/refractory multiple myeloma (RRMM). In this observational, noninterventional European post-authorization safety study, the safety profile of lenalidomide plus dexamethasone was investigated and compared with that of other agents in the treatment of RRMM in a real-world setting.Patients and MethodsPatients had received ≥ 1 prior antimyeloma therapy; prior lenalidomide was excluded. Treatment was per investigator’s routine practice. Adverse events were analyzed by incidence rates per 100 person-years to account for differences in observation length and treatment duration.ResultsIn total, 2150 patients initiated lenalidomide, and 1479 initiated any other antimyeloma therapy, predominately bortezomib (80.3%), which was primarily administered intravenously (74.3%). The incidence rate of neuropathy was lower with lenalidomide (10.5) than with bortezomib (78.9) or thalidomide (38.7). Lenalidomide also had a lower incidence rate of infections (68.7) versus bortezomib (95.9) and thalidomide (76.0). Conversely, the incidence rate of neutropenia was higher with lenalidomide (38.0) than with bortezomib (18.2) or thalidomide (25.7). The incidence rates of thrombocytopenia were 24.4, 40.4, and 14.4 with lenalidomide, bortezomib, and thalidomide, respectively.ConclusionNo new safety signals for lenalidomide were identified in this study, which is the largest prospective real-world European study of lenalidomide in patients with RRMM to date. These results confirm that the safety profile of lenalidomide plus dexamethasone in RRMM in a real-world setting is comparable to that reported in clinical trials. 相似文献
66.
Although hepatitis E virus (HEV) is the primary cause of enterically transmitted acute hepatitis and jaundice in developing countries, locally acquired HEV infections are increasing in nonendemic countries. As such, HEV is emerging as an underdiagnosed cause of infection. This report describes three clinically variable cases of HEV infection with unusual clinical presentations. These cases highlight the fact that HEV should be considered in the differential diagnosis of patients with unexplained hepatitis (acute or chronic) with or without extrahepatic manifestations. HEV should also be considered in patients with persistently elevated liver enzymes who have not travelled to known HEV-endemic regions. Lack of knowledge among physicians and an absence of standardized diagnostic tests may result in increased morbidity and mortality from HEV infection. 相似文献
67.
Andac Salman Deniz Yucelten Ozlem Akin Cakici Eda Kepenekli Kadayifci 《Pediatric dermatology》2019,36(4):514-516
Acute generalized exanthematous pustulosis (AGEP) is seen uncommonly in children and sometimes shows atypical clinical features in this population. Patch testing can be used effectively in children for the confirmation of the culprit drug in cases of multiple drug use. Here, we report a rare, pediatric case of ceftriaxone‐induced AGEP confirmed by patch testing with subsequent recurrence of the skin eruption. 相似文献
68.
目的:观察优化温针灸流程对患者温针灸过程中不良事件发生及舒适度的影响。方法:选取行温针灸治疗的140例患者为研究对象,按随机数字表法分为观察组和对照组各70例。对照组采用传统纸片承接散灰,观察组使用锡纸圆杯代替传统纸片。结果:观察组无不良事件发生。对照组出现不良事件频率较高,其中灰烬跌落床单和灰烬跌落皮肤发生率与观察组比较,差异均有统计学意义(P<0.05)。观察组舒适度优于对照组,差异有统计学意义(P<0.05)。结论:优化温针灸流程在温针灸过程中能减少不良事件发生,提高患者的舒适度。 相似文献
69.
《Revue neurologique》2022,178(8):812-816
IntroductionAs an immune-mediated disease of the central nervous system, multifaceted aspects of a humoral immune response are widely described during multiple sclerosis (MS). However, the prevalence of different auto-antibodies, such as antinuclear antibodies (ANA), during MS is very variable and their clinical relevance remains controversial. Our aim was to evaluate the prevalence and clinical correlations of ANA positivity in South Tunisian MS patients.Material and methodsWe performed ANA screening using indirect immunofluorescence (IIF) on HEp-2 cells (Biosystems®) in 82 MS patients. For ANA positive samples (titer ≥1/160), anti-ds-DNA detection (IIF on Crithidia luciliae (Biosystems®)) and extractable nuclear antigen typing (immunodot (Euroimmun®)) were performed.ResultsANA were positive in 35/82 MS patients (42.7%). The titer was ≥ 1/320 in 16/35 patients. The antigenic specificity of ANA was identified in 7/35 patients. None of the patients had extra-neurological manifestations. No correlation was found between ANA and age, gender, MS course, disease duration, disability, annual relapse rate nor IgG index. ANA positivity was more frequent in patients with IgG oligoclonal bands (OCB) (47.1%) than in patients without IgG OCB (16,6%) (p = 0.049). Regarding disease activity, ANA positivity was significantly more frequent in patients with relapse (52.6%) than in patients in remission (25.9%) (p = 0.031).ConclusionOur results showed that ANA positivity in MS disease is not rare. This positivity was not associated with clinical expression of any connective tissue disease. ANA occurrence in MS was associated with IgG OCB+ profile and relapsing status, probably reflecting an ongoing immune dysregulation. 相似文献
70.